• IBMs cloud CTO Were in this game to win

    Computerworld | An industry focus is one of the key factors IBM is betting will set it apart from cloud competitors including Google, Microsoft and Amazon Web Services, IBM's top cloud exec says.

    Jul 29, 2016

  • How Focusing On Obscure Diseases Made BioMarin A $15 Billion Company

    Forbes | BioMarin became one of the world's most valuable biotechs by jettisoning costly distractions and focusing on one thing: treating some of the rarest diseases on the planet.

    Jul 28, 2016

  • Taking Genomic Data Global

    MIT Technology Review | Startups focused on Asia are among those aiming to bring precision medicine to far more people.

    Jul 28, 2016

  • Microsoft’s Iowa data center cluster to reach 3.2M square feet

    Computerworld | Microsoft is creating some 3.2 million square feet of data center space in the West Des Moines, Iowa, area but in three separate locations. The combined investment is about $3.5 billion.

    Jul 28, 2016

  • Eli Lilly CEO Lechleiter to Retire After Eight-Year Stint

    Xconomy | After eight years at the helm of Eli Lilly, a tenure characterized by a steadfast belief in home-grown research, rather than deals, John Lechleiter is retiring. David Ricks, who currently runs Lilly's diversified bio-medicines unit-which develops drugs for neurological and cardiovascular disorders, among other diseases-will be named CEO on Jan. 1

    Jul 27, 2016

  • Time to Remodel the Journal Impact Factor

    Nature News & Comment | Nature and the Nature journals are diversifying their presentation of performance indicators. Impact factor is crude and also misleading. It effectively undervalues papers in disciplines that are slow-burning or have lower characteristic citation rates. Accordingly, Nature has updated its online journal metrics page to include an array of additional bibliometric data.

    Jul 27, 2016

  • Nvidias Quadro P6000 GPU blasts out 12 teraflops of performance

    Computerworld | Nvidia keeps upping the performance with each new GPU based on the Pascal architecture. Its latest, the Quadro P6000, can deliver 12 teraflops of single-precision performance, a teraflop more than the Titan X unveiled just last week.

    Jul 26, 2016

  • Inside Genomics Pioneer Craig Venter’s Latest Production

    MIT Technology Review | His startup is using data to unlock the connections between DNA and illness.

    Jul 25, 2016

  • Chinese scientists to pioneer first human CRISPR trial

    Nature News & Comment | Gene-editing technique to treat lung cancer is due to be tested in people in August. Sichuan University's West China Hospital in Chengdu plans to inject lung cancer patients with cells modified using the CRISPR-Cas9 gene-editing technique. The clinical trial received ethical approval from the hospital July 6.

    Jul 22, 2016

  • Bioz Launches Life Sciences Search Engine

    Bio-IT World | Bioz, Inc. came out of stealth today with the introduction of a search engine for life science experimentation. The company, started by Stanford research scientist Karin Lachmi and serial entrepreneur Daniel Levitt, also announced $3 million in seed funding, led by 5AM Ventures.

    Jul 20, 2016

  • The Seven Bridges CGC: Boon for Bioinformatics, Success for a Startup

    Bio-IT World It's been a busy two years for Seven Bridges. In May 2014, Seven Bridges was introducing its open source cancer informatics pipeline: open source algorithms running on the proprietary Seven Bridges cloud infrastructure. Less than six months later, the company was awarded one of three National Cancer Institute Cloud Pilot contracts.

    Jul 19, 2016

  • Systems Toxicology Computational Challenge Results Announced

    Bio-IT World | The Systems Toxicology Computational Challenge results have been announced from the fourth challenge launched by sbv IMPROVER, an international scientific crowdsourcing initiative.

    Jul 18, 2016

  • Appistry’s Vision for Clinical Lab Analysis

    Bio-IT World | Appistry launches managed services for clinical sequencing, incorporating GenomePilot, and covering the entire pipeline from when data comes off the sequencers to results analysis.

    Jul 14, 2016

  • With new owner the hated impact factor is overdue for change

    STAT | The impact factor is a poor measure of a journal's quality, and academics say it should either be overhauled or done away with entirely.

    Jul 14, 2016

  • Wellcome Trust launches open-access publishing venture

    Nature News & Comment | Wellcome Open Research is meant to allow Wellcome grant recipients to publish their findings more quickly. The charity hopes other funders will follow a similar model. Management of the venture will be contracted to F1000Research.

    Jul 13, 2016

  • Genomic Medicine Training, New Storage Options, Food Allergy Science

    Bio-IT World | News and product launches from around the Bio-IT landscape include a postdoctoral fellowship in genomics medicine in Alabama, a synthetic biology partnership, new Lustre storage, and the Broad's food allergy science institute.

    Jul 12, 2016

  • A Drug For Postpartum Depression? Sage Passes Early Test With Experimental Treatment

    Forbes | Encouraging news is out today for the treatment of severe postpartum depression. Sage Therapeutics, a biotech company in Cambridge, Mass., reported that its experimental drug was able to relieve severe symptoms of postpartum depression for 70% of patients within a few days, and keep them in remission for a month.

    Jul 12, 2016

  • Intel's Cancer Cloud: Complementing NCI Collaboration

    Bio-IT World | Intel may have missed out on a major government grant, but that hasn't stopped it from developing a collaborative cloud for genomicists and bioinformaticians that it wanted to build all along.

    Jul 11, 2016

  • IT spending will shrink worldwide due to Brexit Gartner predicts

    Computerworld | Britain's vote to exit the European Union will depress global IT spending, according to Gartner analyst John-David Lovelock.

    Jul 8, 2016

  • Juno Therapeutics Stops Trial Of Cancer-Killing Cells After 3 Patient Deaths

    Forbes | Three patients have died in a closely watched study of using genetically engineered white blood cells to treat adult leukemia patients, forcing the trial to be put on hold. The news is a blow for Juno Therapeutics, the biotechnology startup valued at $4.3 billion.

    Jul 8, 2016